The addition of nintedanib (Ofev) to standard of care pemetrexed (Alimta) plus cisplatin failed to delay disease progression in patients with [ unresectable mesothelioma ], according to phase III results of the LUME-Meso study.
After a median treatment duration of more than 5 months, median progression-free survival was 6.8 months for patients assigned to nintedanib, an oral triple angiokinase inhibitor, compared with 7.0 months for those assigned to placebo (P=0.91), reported Giorgio V. Scagliotti, MD, PhD, of the University of Turin, San Luigi Hospital in Italy, and colleagues.
“Despite promising data from the phase II part of the LUME-Meso study, the primary endpoint (progression-free survival) was not met in the phase III part,” they wrote in the Lancet Respiratory Medicine. “New treatment options are still needed in patients with [ unresectable mesothelioma ].”
In an editorial that accompanied the research, Michele Maio, MD, PhD, and Luana Calabrò, MD, PhD, both of the Center for Immuno-Oncology and the University Hospital of Siena in Italy, noted that the LUME-Meso trial is another in a series of trials over the last decade that have “now failed to demonstrate therapeutic efficacy from the targeting of angiogenesis with anti-vascular endothelial growth factor monoclonal antibodies, as well as with multitargeted small-molecule protein kinase inhibitors.”